This is an outdated version published on 2021-07-03. Read the most recent version.

Transcatheter Aortic Valve Implantation (TAVI) and Mitral Valve Transcatheter Edge-To-Edge Repair (TEER): Current Frontiers and Horizons

TAVI and Mitral Valve Transcatheter Edge-To-Edge Repair


  • Catherine Liontou Evafelismos Hospital, Athens
  • Dimitrios Ikonomou Evagelismos Hospital, Athens
  • Konstantinos Triantafyllou Evagelismos Hospital, Athens


During the last two decades transcatheter aortic valve implantation (TAVI) and mitral valve transcatheter edge-to-edge repair (TEER) have evolved in parallel to provide percutaneous interventional treatment solutions for patients with the two most common valvular heart diseases, aortic stenosis and mitral regurgitation, respectively. Having initially been conceived and used to treat patients considered inoperable, TAVI indications have been expanded to include high operative risk and more recently moderate or even low risk patients. The TAVI techniques have also improved to permit tackling challenging complex anatomies and bioprosthetic valve degeneration and structural failure. Similarly, TEER has been initially used to treat inoperable patients with severe symptomatic primary mitral regurgitation (MR), but recently published data have shown that it can provide benefit in carefully selected patients with refractory to optimal medical treatment (OMT) symptomatic severe secondary MR. Furthermore, apart from TEER with the traditional MitraClip system and its iterations, a second TEER system (Pascal) has provided promising results in initial clinical trials and can alternatively be used. We attempt herein a concise overview of the TAVI and mitral valve TEER current state of play. Rhythmos 2021;16(3): 57-61